Bryan, Alexis S.
Moran, Andrew E. http://orcid.org/0000-0003-3554-0085
Mobley, Claire M.
Derington, Catherine G. http://orcid.org/0000-0001-7382-4607
Rodgers, Anthony
Zhang, Yiyi http://orcid.org/0000-0002-8663-5001
Fontil, Valy
Shea, Steven
Bellows, Brandon K. http://orcid.org/0000-0003-1395-6047
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL130500, R01HL158790, K23HL136899, K01HL140170)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
Article History
Received: 28 October 2022
Revised: 26 January 2023
Accepted: 3 February 2023
First Online: 15 February 2023
Competing interests
: CGD reports research funds to her institution from Amarin Pharma, Inc. AR is employed by The George Institute for Global Health (TGI) and Imperial College London. He is seconded part-time to George Medicines Pty Ltd (GM), which is partly owned by George Health Enterprises (GHE), the social enterprise arm of TGI. TGI holds patents for ultra-low-dose fixed-dose combination products for the treatment of hypertension and diabetes, and AR is listed as one of the inventors (US 10,369,15; US 10,799,487; US 10,322,117; US 11,033,544). GHE and GM have received funding from public and private investors to conduct the research required for regulatory approval of cardiovascular combination products. AR does not have a financial interest in these patent applications or investments.